Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls

Journal of Medical Virology

Volumn 83, Issue 4, 2011, Pages 665-678

  Paramita, Dewi K ^a   Fatmawati, Christien ^a   Juwana, Hedy ^b   Van Schaijk, Frank G ^b   Fachiroh, Jajah ^a   Haryana, Sofia M ^a   Middeldorp, Jaap M ^b  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BARF1; Epstein Barr virus; IgA; IgG; LMP1; LMP2; Nasopharyngeal carcinoma

Indexed keywords

BARF1 PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EXPERIMENTAL RABBIT; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR CELL;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NASOPHARYNGEAL NEOPLASMS;

HUMAN HERPESVIRUS 4; ORYCTOLAGUS CUNICULUS;

EID: 79951525234     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21960     Document Type: Article

References (57)

1. Bernasconi M, Berger C, Sigrist JA, Bonanomi A, Sobek J, Niggli FK, Nadal D. 2006. Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray. Virol J 3: 43.
2. Brink AA, Vervoort MB, Middeldorp JM, Meijer CJ, van den Brule AJ. 1998. Nucleic acid sequence-based amplification, a new method for analysis of spliced and unspliced Epstein-Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. J Clin Microbiol 36: 3164-3169.
3. Brooks L, Yao QY, Rickinson AB, Young LS. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66: 2689-2697.
4. Chen HF, Kevan-Jah S, Suentzenich KO, Grasser FA, Mueller-Lantzsch N. 1992. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 190: 106-115.
5. Cheng WM, Chan KH, Chen HL, Luo RX, Ng SP, Luk W, Zheng BJ, Ji MF, Liang JS, Sham JS, Wang DK, Zong YS, Ng MH. 2002. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 97: 489-492.
6. Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P. 2004. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 15: 113-117.
7. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. 2005. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23: 8942-8949.
8. Dantuma NP, Sharipo A, Masucci MG. 2002. Avoiding proteasomal processing: The case of EBNA1. Curr Top Microbiol Immunol 269: 23-36.
9. De Bruin PC, Jiwa NM, Van der Valk P, Van Heerde P, Gordijn R, Ossenkoppele GJ, Walboomers JM, Meijer CJ. 1993. Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas: Relation between latent membrane protein-1 positivity and clinical course. Histopathology 23: 509-518.
10. de Turenne-Tessier M, Jolicoeur P, Middeldorp JM, Ooka T. 2005. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system. Virus Res 109: 9-18.
11. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, Bouguermouh A, Ooka T. 2000. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 60: 5584-5588.
12. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM. 2000. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 165: 663-670.
13. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1: 702-703.
14. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM. 2004. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: A comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190: 53-62.
15. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM. 2006. Single-assay combination of Epstein-Barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: Options for field screening. J Clin Microbiol 44: 1459-1467.
16. Floettmann JE, Ward K, Rickinson AB, Rowe M. 1996. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 223: 29-40.
17. Frech B, Zimber-Strobl U, Yip TT, Lau WH, Mueller-Lantzsch N. 1993. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 74: 811-818.
18. Fruehling S, Lee SK, Herrold R, Frech B, Laux G, Kremmer E, Grasser FA, Longnecker R. 1996. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70: 6216-6226.
19. Henle W, Henle GE, Horwitz CA. 1974. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5: 551-565.
20. Heussinger N, Buttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, Niedobitek G. 2004. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 203: 696-699.
21. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
22. Kapatai G, Murray P. 2007. Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 60: 1342-1349.
23. Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM. 2005. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 75: 593-602.
24. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquere S, Nishi N, Hirashima M, Middeldorp J, Busson P. 2006. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6: 283.
25. Khabir A, Karray H, Rodriguez S, Rose M, Daoud J, Frikha M, Boudawara T, Middeldorp J, Jlidi R, Busson P. 2005. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2: 39.
26. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176: 169-176.
27. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, Adhikary D, Mautner J, Busson P. 2009. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957-1966.
28. Lennette ET, Winberg G, Yadav M, Enblad G, Klein G. 1995. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 31A: 1875-1878.
29. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685-688.
30. Marshall NA, Vickers MA, Barker RN. 2003. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 170: 6183-6189.
31. Martorelli D, Houali K, Caggiari L, Vaccher E, Barzan L, Franchin G, Gloghini A, Pavan A, Da Ponte A, Tedeschi RM, De Re V, Carbone A, Ooka T, De Paoli P, Dolcetti R. 2008. Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. Int J Cancer 123: 1100-1107.
32. Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM. 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 179: 1108-1115.
33. Meij P, Vervoort MB, de Gooijer K, Bloemena E, Meijer CJ, Middeldorp JM. 2000a. Bioreactor-scale production and one-step purification of Epstein-Barr nuclear antigen 1 expressed in baculovirus-infected insect cells. Protein Expr Purif 20: 324-333.
34. Meij P, Vervoort MB, Meijer CJ, Bloemena E, Middeldorp JM. 2000b. Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. J Virol Methods 90: 193-204.
35. Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, Ambinder RF, Middeldorp JM. 2002. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol 68: 370-377.
36. Middeldorp J. 2002. Method for the identification of extracellular domains of Epstein-Barr virus (EBV) tumor-associated latent membrane proteins and selection of antibody reagents reactive therewith. International patent WO02/060902 A2.
37. Middeldorp JM, Meloen RH. 1988. Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. J Virol Methods 21: 147-159.
38. Modrow S, Wolf H. 1986. Characterization of two related Epstein-Barr virus-encoded membrane proteins that are differentially expressed in Burkitt lymphoma and in vitro-transformed cell lines. Proc Natl Acad Sci USA 83: 5703-5707.
39. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176: 157-168.
40. Ng WT, Yau TK, Yung RW, Sze WM, Tsang AH, Law AL, Lee AW. 2005. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 113: 998-1001.
41. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM. 2007. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 79: 1710-1721.
42. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. 2008. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. J Clin Virol 42: 343-352.
43. Rickinson A, Kieff E. 2007. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology, 5th edition. Philadelphia: Lippincott, Williams & Wilkin. pp 2656-2700.
44. Rowe M, Finke J, Szigeti R, Klein G. 1988. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 69: 1217-1228.
45. Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, Takada K. 2005. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 76: 82-88.
46. Snow AL, Martinez OM. 2007. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 7: 271-277.
47. Sulitzeanu D, Szigeti R, Hatzubai A, Dillner J, Hammarskjold ML, Klein G, Klein E. 1988. Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). Immunol Lett 18: 301-306.
48. Swanson-Mungerson M, Ikeda M, Lev L, Longnecker R, Portis T. 2003. Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases. J Antimicrob Chemother 52: 152-154.
49. Tanner JE, Wei MX, Alfieri C, Ahmad A, Taylor P, Ooka T, Menezes J. 1997. Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J Infect Dis 175: 38-46.
50. Thorley-Lawson DA. 2001. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 1: 75-82.
51. Timmerman P, Beld J, Puijk WC, Meloen RH. 2005. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem 6: 821-824.
52. van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ, Bloemena E. 2004. EBV-positive gastric adenocarcinomas: A distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22: 664-670.
53. van Gorp J, Brink A, Oudejans JJ, van den Brule AJ, van den Tweel JG, Jiwa NM, de Bruin PC, Meijer CJ. 1996. Expression of Epstein-Barr virus encoded latent genes in nasal T cell lymphomas. J Clin Pathol 49: 72-76.
54. Wiertz EJ, Devlin R, Collins HL, Ressing ME. 2007. Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation. J Virol 81: 4389-4396.
55. Wu TC, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, Ambinder RF. 1990. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 46: 801-804.
56. + T cells through an additional host shutoff function. J Virol 82: 2385-2393.
57. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228: 1056-1058.